- Home
- PLRX vs CRMD Comparison
PLRX vs CRMD Comparison
Compare PLRX & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLRX | CRMD |
|---|---|---|
| Founded | 2015 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.9M | 509.9M |
| IPO Year | 2020 | 2009 |
Fundamental Metrics
Financial Performance| Metric | PLRX | CRMD |
|---|---|---|
| Price | $1.29 | $6.86 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $2.67 | ★ $14.67 |
| AVG Volume (30 Days) | 475.5K | ★ 1.5M |
| Earning Date | 03-11-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 29.97 | ★ 780.00 |
| EPS | N/A | ★ 2.04 |
| Revenue | N/A | ★ $311,709,000.00 |
| Revenue This Year | N/A | $0.30 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $3.22 |
| Revenue Growth | N/A | ★ 617.03 |
| 52 Week Low | $1.09 | $5.60 |
| 52 Week High | $1.95 | $17.43 |
Technical Indicators
Market Signals| Indicator | PLRX | CRMD |
|---|---|---|
| Relative Strength Index (RSI) | 51.24 | 52.05 |
| Support Level | $1.12 | $6.55 |
| Resistance Level | $1.39 | $7.44 |
| Average True Range (ATR) | 0.08 | 0.25 |
| MACD | -0.01 | 0.09 |
| Stochastic Oscillator | 49.15 | 86.53 |
Price Performance
Historical ComparisonAbout PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.